Dexrazoxane prevents doxorubicin‐induced long‐term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats
- 1 July 2007
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 151 (6), 771-778
- https://doi.org/10.1038/sj.bjp.0707294
Abstract
Doxorubicin causes a chronic cardiomyopathy in which reactive oxygen species (ROS) accumulate over time and are associated with genetic and functional lesions of mitochondria. Dexrazoxane is a cardioprotective iron chelator that interferes with ROS production. We aim to analyze the effects of dexrazoxane on mitochondria in the prevention of doxorubicin-induced chronic myocardial lesions. Wistar rats (11 weeks of age) were injected with intravenous doxorubicin (0.8 mg kg(-1) weekly for 7 weeks) with or without simultaneous dexrazoxane (8 mg kg(-1)). Animals were killed at 48 weeks. Cardiomyopathy was scored clinically and histologically and cardiac mitochondria were analyzed. Compared to control rats receiving saline, rats treated with doxorubicin alone developed a clinical, macroscopic, histological and ultrastructural cardiomyopathy with low cytochrome c-oxidase (COX) activity (26% of controls). The expression of the mtDNA-encoded COX II subunit was reduced (64% of controls). Myocardia exhibited a high production of ROS (malondialdehyde 338% and superoxide 787% of controls). Mitochondria were depleted of mitochondrial DNA (mtDNA copy number 46% of controls) and contained elevated levels of mtDNA deletions. Dexrazoxane co-administration prevented all these effects of doxorubicin on mitochondria, except that hearts co-exposed to doxorubicin and dexrazoxane had a slightly lower mtDNA content (81% of controls) and mtDNA deletions at low frequency. Dexrazoxane prevented doxorubicin induced late-onset cardiomyopathy and also protected the cardiac mitochondria from acquired ultrastructural, genetic and functional damage.This publication has 41 references indexed in Scilit:
- Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stressJournal of Molecular and Cellular Cardiology, 2007
- Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well?British Journal of Pharmacology, 2006
- Transcriptional analysis of doxorubicin-induced cardiotoxicityAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicinThe Journal of Pathology, 2005
- Nitrosative stress and pharmacological modulation of heart failureTrends in Pharmacological Sciences, 2005
- Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac DysfunctionCirculation, 2003
- Dexrazoxane pre‐treatment protects skinned rat cardiac trabeculae against delayed doxorubicin‐induced impairment of crossbridge kineticsBritish Journal of Pharmacology, 2002
- Long-Lasting Effect of Dexrazoxane Against Anthracycline Cardiotoxicity in RatsToxicologic Pathology, 1996
- Pharmacokinetics of the Cardioprotector ADR-529 (ICRF-187) in Escalating Doses Combined With Fixed-Dose DoxorubicinJNCI Journal of the National Cancer Institute, 1992
- Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicityPharmacology & Therapeutics, 1990